Stock Events

Stock Events

Lineage Cell Therapeutics 

€1.16
0
+€0.02+1.75% Today

Statistics

Day High
1.17
Day Low
1.14
52W High
1.65
52W Low
0.36
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q4 2025
Next
-0.04
-0.02
-0.01
0
Expected EPS
-0.016994000000000002
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BT3.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stem
STEM
Mkt Cap82.05M
StemCells, Inc. focuses on cell-based therapeutics, directly competing in the regenerative medicine space with Lineage Cell Therapeutics.
Biolife Solutions
BLFS
Mkt Cap1.04B
BioLife Solutions, Inc. provides bioproduction tools and services, including cell and gene therapy solutions, indirectly competing with Lineage's operational needs.
CRISPR Therapeutics
CRSP
Mkt Cap5.29B
CRISPR Therapeutics AG focuses on gene editing, a technology that could potentially compete with or complement Lineage's cell therapy approaches.
Editas Medicine
EDIT
Mkt Cap304.49M
Editas Medicine, Inc. is involved in gene editing, representing a competitive or complementary approach to Lineage's cell-based therapies.
Vericel
VCEL
Mkt Cap1.81B
Vericel Corporation focuses on autologous cell therapies for the treatment of patients with serious diseases, directly competing in the regenerative medicine sector.
Mesoblast
MESO
Mkt Cap1.91B
Mesoblast Limited specializes in regenerative medicine, developing mesenchymal lineage adult stem cell therapies, closely competing with Lineage's therapeutic approaches.
Fate Therapeutics
FATE
Mkt Cap277.91M
Fate Therapeutics, Inc. is dedicated to the development of programmed cellular immunotherapies, competing in the broader cell therapy market.

About

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Show more...
CEO
Mr. Brian M. Culley M.A., M.B.A.
Employees
70
Country
United States
ISIN
US53566P1093

Listings

STU
DE
BT3.STU
XASE
US
LCTX
F
DE
BT3.F
TA
IL
LCTX.TA

0 Comments

Share your thoughts

FAQ

What is Lineage Cell Therapeutics stock price today?▼
The current price of BT3.STU is €1.16 EUR — it has increased by +1.75% in the past 24 hours. Watch Lineage Cell Therapeutics stock price performance more closely on the chart.
What is Lineage Cell Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lineage Cell Therapeutics stocks are traded under the ticker BT3.STU.
Is Lineage Cell Therapeutics stock price growing?▼
BT3.STU stock has fallen by -3.65% compared to the previous week, the month change is a -6.29% fall, over the last year Lineage Cell Therapeutics has showed a +204.19% increase.
When is the next Lineage Cell Therapeutics earnings date?▼
Lineage Cell Therapeutics is going to release the next earnings report on May 12, 2026.
What were Lineage Cell Therapeutics earnings last quarter?▼
BT3.STU earnings for the last quarter are 0 EUR per share, whereas the estimation was -0.04 EUR resulting in a +109.33% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Lineage Cell Therapeutics have?▼
As of May 11, 2026, the company has 70 employees.
In which sector is Lineage Cell Therapeutics located?▼
Lineage Cell Therapeutics operates in the Health & Wellness sector.
When did Lineage Cell Therapeutics complete a stock split?▼
Lineage Cell Therapeutics has not had any recent stock splits.
Where is Lineage Cell Therapeutics headquartered?▼
Lineage Cell Therapeutics is headquartered in Carlsbad, United States.